Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON‐TIMI 38
- 1 August 2009
- journal article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 49 (8) , 984-998
Abstract
Serial pharmacokinetic (PK) sampling in 1159 patients from TRITON‐TIMI 38 was undertaken. A multilinear regression model was used to quantitatively predict prasugrel's active metabolite (Pras‐AM) concentrations from its 2 downstream inactive metabolites. Population‐based methods were then applied to Pras‐AM concentration data to characterize the PK. The potential influence of body weight, body mass index, age, sex, renal function, diabetes, tobacco use, and other disease status on Bayesian estimates of Pras‐AM exposures was assessed. The PK of Pras‐AM was adequately described by a multicompartmental model and consistent with results from previous studies. The systemic exposure of prasugrel was not appreciably affected by body mass index, gender, diabetes, smoking, and renal impairment. Pras‐AM mean exposure in patients weighing <60 kg (4.1%) was 30% (90% confidence interval [CI] 1.16–1.45) higher than exposure in patients ≥60 kg. Mean Pras‐AM exposures for patients ≥75 years (10.5%) were 19% (90% CI: 1.11–1.28) higher compared with patients <75 years.Keywords
This publication has 22 references indexed in Scilit:
- Prasugrel, a New Thienopyridine Antiplatelet Drug, Weakly Inhibits Cytochrome P450 2B6 in HumansThe Journal of Clinical Pharmacology, 2008
- Prasugrel: A Novel Thienopyridine Antiplatelet Agent. A Review of Preclinical and Clinical Studies and the Mechanistic Basis for Its Distinct Antiplatelet ProfileCardiovascular Drug Reviews, 2007
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose ClopidogrelJournal of Cardiovascular Pharmacology, 2007
- Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery diseaseEuropean Heart Journal, 2006
- INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450Drug Metabolism and Disposition, 2006
- ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary ArticleJACC, 2006
- Pharmacology of CS-747 (prasugrel, LY640315), a Novel, Potent Antiplatelet Agent with in Vivo P2Y12Receptor Antagonist ActivitySeminars in Thrombosis and Hemostasis, 2005
- Clopidogrel and Ticlopidine: P2Y12Adenosine Diphosphate-Receptor Antagonists for the Prevention of AtherothrombosisSeminars in Thrombosis and Hemostasis, 2005
- Specific Impairment of Human Platelet P2Y AC ADP Receptor–Mediated Signaling by the Antiplatelet Drug ClopidogrelArteriosclerosis, Thrombosis, and Vascular Biology, 1999